Efficacy of Tofacitinib in Pediatric Alopecia Universalis

The document described a case study where a 16-year-old male with alopecia universalis (AU), who had not responded to previous treatments, experienced significant hair regrowth after five months of treatment with tofacitinib, a JAK1/3 inhibitor. The patient took 5 mg of tofacitinib orally twice daily and saw hair regrowth on the scalp, eyebrows, arms, and legs, with increased appetite and weight gain as the only side effects. Blood tests remained normal throughout the treatment. This case suggests that JAK inhibitors could be a promising treatment for pediatric AU, but further research is necessary to confirm their efficacy and establish the best treatment protocols.